Variation in detection of VEGF in maternal serum by immunoassay and the possible influence of binding proteins

Annals of Clinical Biochemistry

Volumn 34, Issue 3, 1997, Pages 276-280

  Anthony, F W ^a   Evans, P W ^a   Wheeler, T ^a   Wood, P J ^b  

^a PRINCESS ANNE HOSPITAL   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Implantation; Placenta; Soluble receptor

Indexed keywords

BINDING PROTEIN; POLYCLONAL ANTIBODY; VASCULOTROPIN;

ARTICLE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MATERNAL SERUM; NORMAL HUMAN; PREGNANCY; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0031001133     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1177/000456329703400309     Document Type: Article

References (14)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995; 1: 27-31
2. Ferrara N, Houck KA, Jakeman L, Winer J, Leung DW. The Vascular Endothelial Growth Factor Family of Polypeptides. J Cell Biochem 1991; 47: 211-8
3. Shalaby F, Rossant J, Yamaguchi TP, Gertenstein M, Wu XF, Breitman ML, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62-6
4. Fong GH, Rossant J, Gertenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66-70
5. Charnock-Jones DS, Sharkey AM, Boocock CA, Ahmed A, Plevin R, Ferrara N, et al. Vascular endothelial growth factor receptor localisation and activation in human trophoblast and choriocarcinoma cells. Biol Reprod 1994; 51: 524-30
6. Heney D, Whicher JT. Factors affecting the measurement of cytokines in biological fluids: implications for their clinical measurement. Ann Clin Biochem 1995; 32: 358-68
7. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992; 267: 26031-7
8. Balkwill F, Osborne R, Burke F, Naylor S, Talbot D, Durbin H, et al. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet 1987; ii: 1229-32
9. Selby PJ, Hobbs S, Vino C, Jackson E, Smith IE, McElwain TH. Endogenous tumour necrosis factor in cancer patients. Lancet 1988; i: 934-5
10. Baker PN, Krasnow J, Roberts JM, Kiang-Teck Yeo. Elevated Serum Levels of Vascular Endothelial Growth Factor in Patients with Preeclampsia. Obstet Gynecol 1995; 86: 815-21
11. 2-macroglobulin and the binding is inhibited by heparin. J Biol Chem 1993; 268: 7685-91
12. Charnock-Jones DS, Sharkey AM, Day K, Smith SK. Identification and characterisation of soluble variants of vascular endothelial growth factor (VEGF) receptors in the human placenta. Placenta 1995; 16: A11, VIth meeting of the European Placenta Group
13. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705-9
14. Engelberts I, Stephens S, Francot GJM, van der Linden CJ, Buurman WA. Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 1991; ii: 515-6